Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug

(MedPage Today) — The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday.
A pair of pyrimidine nucleosides, the doxecitine…